key: cord-0704157-0ux8kiqz authors: Lui, Thomas KL.; Leung, Kathy; Guo, Chuan-Guo; Tsui, Vivien WM.; Wu, Joseph T.; Leung, Wai K. title: Impacts of COVID-19 Pandemic on Gastrointestinal Endoscopy Volume and Diagnosis of Gastric and Colorectal Cancers: A Population-based Study date: 2020-05-17 journal: Gastroenterology DOI: 10.1053/j.gastro.2020.05.037 sha: cdf7bfd05e870b7fe7be6a88016ea9bd2f192c42 doc_id: 704157 cord_uid: 0ux8kiqz nan The coronavirus disease (COVID-19) pandemic has caused a major disruption to our healthcare system. In response to the service demand surge and shortage of personal protective equipment, multiple professional societies have issued recommendation to defer elective endoscopic procedures, except time-sensitive and emergency procedures. [1] [2] [3] As yet, the real-life impact of this pragmatic service reduction is unknown. Herein, we reported the short-term impacts of the COVID-19 pandemic on the volume of gastrointestinal endoscopy and new diagnosis of gastric and colon cancers in Hong Kong, and modelled on the changes in cancer staging. The first local COVID-19 case was reported on 23 January 2020 and till May 8 2020, a total and 58.8% (from 1190 to 491, p<0.001), respectively. The mean gastric cancer and colorectal cancer diagnosed per week also fell by 46.2% (from 22.9 to 12.3, p < 0.001) and 37.0% (from 92.1 to 58, p<0.001), respectively. Notably, the positive rates (per 1,000 endoscopy) for gastric cancer remained static throughout these periods (11.8 to 13.9, p =0.14; Supplementary For gastric cancer, the ARIMA(0,1,1)(1,0,1) 26 model with a 26-week cyclical pattern was fitted with data from previous years. The mean percentage error (MPE) of the model was 2.5% and 3.5% for the training set and test set, respectively. For colorectal cancer, the MPE of the ARIMA(0,0,1)(1,0,1) 26 model was 2.8% and 3.3%, respectively. For the 10-week period starting from 21 January 2020, the predicted number of gastric cancer and colorectal cancer This is the first study to quantify the disruption brought by the COVID-19 pandemic on the delivery of gastrointestinal endoscopy and its impacts on cancer diagnosis and staging at a population level. While the volume of endoscopy was reduced by more than 50% in Hong Kong, the number of patients diagnosed with gastric and colorectal cancer dropped by 49.1% and 38.1%, respectively. Based on the ARIMA prediction and Markov model, we estimated that 4.6% and 6.4% of gastric and colorectal patients would have cancer stage upshifting at 6 months. In a recent report from a single hospital in Shanghai China, it was noted that their endoscopy volume dropped by 6.3-times during COVID-19 6 . In another North American survey, 65% of centers were performing less than 10% of their usual volume 7 . However, public hospitals in Hong Kong do not routinely perform screening endoscopy and the potential impacts on delayed cancer diagnosis could be worse than centers that primarily performed screening procedures. Interestingly, we noted that the impact of service reduction on upper endoscopy was more critical than lower colonoscopy as the positive rate for cancer by lower colonoscopy actually increased after the outbreak, suggesting that triage based on lower gastrointestinal symptoms is more reliable than upper gastrointestinal symptoms in arranging early endoscopy. In conclusion, the COVID-19 outbreak has resulted in substantial drop in endoscopy services in Hong Kong, which is associated with significant delay on cancer diagnosis. The delay and subsequent cancer stage upshifting will be amplified if the COVID-19 pandemic lengthens further. Gradual resumption of non-emergency endoscopy services should be considered as early as feasible and practical, balancing the risks of delayed cancer diagnosis and personal safety of patients and staff. Shading area and error bars represented 95% confidence intervals. We analyzed the numbers of upper and lower endoscopy performed; and the number of new cases of gastric cancer and colorectal cancer diagnosed between 1 October and 31 March in each year on a weekly basis. Buishand U test was used to determine the week of turning point of the sudden changes in the numbers of endoscopy performed and the numbers of cancer diagnosed (i.e. week of turning point). The mean number of endoscopies performed and the mean number of cancers diagnosed per week were compared by two sample t-test before and after the turning point. Pearson correlation was used to assess for any association between the number of cancers diagnosed and the volume of endoscopy. The test set started from 1 Oct 2019 to the week of turning point as determined by the Buishand U test for internal and external validation of the model. The mean percentage error (MPE) were used to test the accuracy of the forecast. Based on the numbers of new diagnosis of gastric or colorectal cancer before the week of turning point as determined by the Pettitt's test, ARMIA prediction of the numbers of patients diagnosed with gastric or colorectal cancer was made. The weekly-based data after excluding the lunar new year holiday effect was used in the ARIMA prediction. The difference between the ARIMA prediction and actual number of patients diagnosed with gastric cancer or colorectal cancer were used to estimate the number of patients with delayed cancer diagnosis after the turning point. The baseline stage distribution of colorectal cancer in Hong Kong was: stage I (11.0%), stage II (21.9%), stage III (25.9%), stage IV (23.5%) and unstaged (17.7%) 1 , respectively. The corresponding stage distribution of gastric cancer was: stage I (11.8%), stage II (27.1%), stage III (18.6%), stage IV (30.5%) and unstaged (16.3%). Based on currently available data for gastric cancer, the annual transition rate from stage I to II was 0.20, stage II to III was 0.30 and stage III to IV was 0.40. 2 For colorectal cancer, the annual transition rate for colorectal cancer from stage I to II was 0.58, stage II to III was 0.66 and stage III to IV was 0.83. 3 The potential stage shifting of these cancers with delayed diagnosis were estimated by using a state-transition Markov model. Linear regression models were formulated for the association between upper endoscopy volume and numbers of newly diagnosed gastric cancer; and between lower endoscopy volume and numbers of newly diagnosed colorectal cancer. Hospital Authority. Hong Kong Cancer Registry All statistical analyses were performed by the R statistical software (version 3.2.3; R Foundation for Statistical Computing). Continuous variables were expressed as median and interquartile range (IQR). The Mann-Whitney U-test was used to compare continuous variables between two groups. The Chi-square test or Fisher's exact test, where appropriate, was applied for comparing categorical variables